DNA-Binding Capabilities and Anticancer Activities of Ruthenium(II) Cymene Complexes with (Poly)cyclic Aromatic Diamine Ligands
Open Access
- 26 December 2020
- Vol. 26 (1), 76
- https://doi.org/10.3390/molecules26010076
Abstract
Ruthenium(II) arene complexes of the general formula [RuCl(η6-p-cymene)(diamine)]PF6 (diamine = 1,2-diaminobenzene (1), 2,3-diaminonaphthalene (2), 9,10-diaminophenanthrene (3), 2,3-diaminophenazine (4), and 1,2-diaminoanthraquinone (5) were synthesized. Chloro/aqua exchange was evaluated experimentally for complexes 1 and 2. The exchange process was investigated theoretically for all complexes, revealing relatively fast exchange with no significant influence from the polycyclic aromatic diamines. The calf thymus DNA (CT-DNA) binding of the complexes increased dramatically upon extending the aromatic component of the diamines, as evaluated by changes in absorption spectra upon titration with different concentrations of CT-DNA. An intercalation binding mode was established for the complexes using the increase in the relative viscosity of the CT-DNA following addition of complexes 1 and 2. Theoretical studies showed strong preference for replacement of water by guanine for all the complexes, and relatively strong Ru–Nguanine bonds. The plane of the aromatic systems can assume angles that support non-classical interactions with the DNA and covalent binding, leading to higher binding affinities. The ruthenium arenes illustrated in this study have promising anticancer activities, with the half maximal inhibitory concentration (IC50) values comparable to or better than cisplatin against three cell lines.This publication has 49 references indexed in Scilit:
- Kinetically-inert polypyridylruthenium(II) complexes as therapeutic agentsCoordination Chemistry Reviews, 2018
- A discrete organoplatinum(II) metallacage as a multimodality theranostic platform for cancer photochemotherapyNature Communications, 2018
- Coordination compounds in cancer: Past, present and perspectivesJournal of Applied Biomedicine, 2015
- Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation studyAnti-Cancer Drugs, 2009
- Resistance against novel anticancer metal compounds: Differences and similaritiesDrug Resistance Updates, 2008
- Towards the rational design of platinum(ii) and gold(iii) complexes as antitumour agentsDalton Transactions, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- Platinum Group Antitumor Chemistry: Design and development of New Anticancer Drugs Complementary to CisplatinCurrent Medicinal Chemistry, 2006
- Ruthenium Complexes as Anticancer AgentsCurrent Medicinal Chemistry, 2006
- Current Status of Platinum-Based Antitumor DrugsChemical Reviews, 1999